A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s)
Latest Information Update: 22 Apr 2025
At a glance
- Drugs RO 7673396 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 17 Apr 2025 Status changed from not yet recruiting to recruiting.
- 28 Mar 2025 New trial record